Evommune (EVMN) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Galectin Therapeutics (GALT) has outperformed Evommune (EVMN) over the past year, losing 49.7% versus a loss of 62.4%. Evommune is the larger company by market cap ($291.1 million vs $271.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | GALT |
|---|---|---|
| Share price | $7.04 | $2.69 |
| Market cap | $291.10M | $271.35M |
| 1-day change | -2.76% | -4.27% |
| YTD return | -58.88% | -35.34% |
| 1-year return | -62.37% | -49.72% |
| 5-year return | — | +4.67% |
| EPS (TTM) | $-3.83 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.00M | — |
| Revenue growth (YoY) | +85.71% | — |
| Net income (latest FY) | $-68.87M | $-30.84M |
| Operating margin | -623.62% | — |
| Net margin | -529.77% | — |
| 52-week high | $33.20 | $7.13 |
| 52-week low | $4.94 | $2.03 |
| Distance from 52-week high | -78.80% | -62.27% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +210.94% | +308.92% |
| Average volume | 841.65K | 252.31K |
| Shares outstanding | 41.35M | 100.88M |
| Employees | 48 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GALT has outperformed EVMN by 12.7 percentage points over the past year.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
EVMN vs GALT FAQ
Which is bigger, Evommune or Galectin Therapeutics?
Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $271.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, EVMN or GALT?
GALT returned -49.72% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.
Are Evommune and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.